- Home
- ZNTL vs CRBP Comparison
ZNTL vs CRBP Comparison
Compare ZNTL & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | CRBP |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 134.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | CRBP |
|---|---|---|
| Price | $2.49 | $8.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $6.60 | ★ $46.17 |
| AVG Volume (30 Days) | ★ 623.6K | 145.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.87 | ★ 64.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,425,000.00 | $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $220.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $1.01 | $4.64 |
| 52 Week High | $3.95 | $20.56 |
Technical Indicators
Market Signals| Indicator | ZNTL | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 56.25 |
| Support Level | $1.27 | $8.39 |
| Resistance Level | $2.69 | $8.43 |
| Average True Range (ATR) | 0.17 | 0.48 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 55.17 | 79.61 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.